التفاصيل البيبلوغرافية
| العنوان: |
GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY. |
| المؤلفون: |
Patel, K., Brown, J. R., Desikan, S. P., Nguyen, B., Won, H., Tantawy, S. I., McNeely, S. C., Marella, N., Ebata, K., Woyach, J. A., Tam, C. S., Eyre, T. A., Cheah, C. Y., Shah, N. N., Ghia, P., Jurczak, W., Balbas, M., Nair, B., Abada, P., Wang, C. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p185-187, 3p |
| مصطلحات موضوعية: |
CHRONIC lymphocytic leukemia, SOMATIC mutation |
| مستخلص: |
BMS Honoraria: Roche, Janssen, Gilead, AstraZenecca, Lilly, TG therapeutics, Beigene, Novartis, Menarini, Daizai, Abbvie, Genmab. B Introduction: b Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi, demonstrated efficacy in patients (pts) with CLL resistant to cBTKi. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder